Neurogene (NGNE)

• Market cap: $237M
• 1 day: -4.03%
• 5 days: -14.20%
• 1 month: -29.11%
• 3 months: -68.08%
• 6 months: -63.18%
• Year to date: -30.32%
• 1 year: -47.01%
• 5 years: 5.63%
• 10 years: 5.63%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Employees: 91

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,050% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 2

30% more funds holding

Funds holding: 66 [Q2] → 86 (+20) [Q3]

16% more capital invested

Capital invested by funds: $499M [Q2] → $581M (+$81.8M) [Q3]

0.9% more ownership

Funds ownership: 105.74% [Q2] → 106.64% (+0.9%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 22

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 182% upside
• Avg. target: $61 281% upside
• High target: $72 351% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 27% 1-year accuracy 45 / 166 met price target	245% upside $55	Buy Reiterated	25 Nov 2024
BMO Capital Keith Tapper 40% 1-year accuracy 2 / 5 met price target	182% upside $45	Outperform Maintained	20 Nov 2024
Stifel Paul Matteis 14% 1-year accuracy 2 / 14 met price target	276% upside $60	Buy Maintained	12 Nov 2024
Leerink Partners Mani Foroohar 24% 1-year accuracy 4 / 17 met price target	351% upside $72	Outperform Maintained	12 Nov 2024
Baird Joel Beatty 48% 1-year accuracy 20 / 42 met price target	351% upside $72	Outperform Maintained	12 Nov 2024